THOUSAND OAKS, Calif.–(BUSINESS WIRE) January 16, 2025 — Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for…
THOUSAND OAKS, Calif.–(BUSINESS WIRE) January 16, 2025 — Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for…
No Comments
Leave a comment Cancel